YH41723 / Yuhan Corp, Immuneoncia Therap - LARVOL DELTA

K-anticancer drug is ready for global application as a ‘bio-innovative new drug’ at the US AACR [Google translation] (BioTimes) - "Yuhan Corporation plans to announce preclinical test results of its dual antibody pipelines ‘YH32367’ and ‘YH41723’...Yuhan Corporation is conducting phase 1 clinical trials in Korea and Australia targeting patients who show resistance to existing anticancer treatments in a number of HER2-expressing solid cancers, such as breast cancer, stomach cancer, and biliary tract cancer. We are developing YH32367 with the goal of completing the recruitment of patients for the phase 1 clinical dose escalation trial by the first half of the year and starting a trial to set the optimal dose in the second half of the year."

Enrollment status • Preclinical • Trial status • Oncology • Solid Tumor • HER-2

YH41723 (IMC-202), a Novel TIGITxPD-L1 bispecific antibody, leads to potent anti-tumor immunity through T cell engaging and T/NK cell activation (AACR 2024) - "The tumor-free state of tumor re-challenged mice was sustained, indicating that the immune memory was generated by YH41723. Taken together, YH41723 showed strong efficacy in NK/T cell activation and Treg depletion in vitro and excellent anti-tumor efficacy in vivo, supporting that YH41723 as an effective anti-cancer immunotherapy and combination candidate with other ICIs."

Oncology • CD8 • TIGIT

Yuhan Corporation announces non-clinical results of two types of immunotherapy at the American Cancer Society [Google translation] (Medifonews) - "Yuhan Corporation...will present the results of non-clinical research on YH32367 (ABL105) and YH41723 (IMC202), immunotherapy drugs under development, at the American Association for Cancer Research (AACR 2024)...YH32367 not only showed significantly superior anticancer efficacy and safety compared to control antibodies in various non-clinical experiments on HER2-expressing tumors, but also showed superior efficacy compared to competing drugs even in tumors with low HER2 expression...YH41723 specifically binds to tumor cells expressing PD-L15, a representative target of anti-cancer immunotherapy, and activates T immune cells by interfering with PD-1, which inhibits the activity of T immune cells....Yuhan Corporation aims to start clinical trials for YH41723 in 2025."

New trial • Preclinical • Oncology • Solid Tumor • HER-2